Literature DB >> 11786752

F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy.

Wei-Jen Shih1, Nasrin Ghesani, Zhuang Hongming, Abass Alavi, Steven Schusper, Davis Mozley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11786752     DOI： 10.1097/00003072-200202000-00019

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


× No keyword cloud information.
  6 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

2.  Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation.

Authors:  Luca Quartuccio; Martina Fabris; Sara Salvin; Marta Maset; Ginevra De Marchi; Salvatore De Vita
Journal:  Int J Rheumatol       Date:  2010-01-28

3.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.

Authors:  Raphaèle Seror; Christelle Sordet; Loic Guillevin; Eric Hachulla; Charles Masson; Marc Ittah; Sophie Candon; Véronique Le Guern; Achille Aouba; Jean Sibilia; Jacques-Eric Gottenberg; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-09-01       Impact factor: 19.103

Review 4.  Primary Sjögren's syndrome: new clinical and therapeutic concepts.

Authors:  M Ramos-Casals; A G Tzioufas; J Font
Journal:  Ann Rheum Dis       Date:  2004-10-21       Impact factor: 19.103

5.  [Recurrent abcesses of the parotid gland in Sjögren's syndrome].

Authors:  A Knopf; A Pickhard; T Stark; S Schulz; E Q Scherer
Journal:  HNO       Date:  2009-09       Impact factor: 1.284

6.  Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma.

Authors:  J Carbone; R Perez-Fernandez; A Muñoz; P Sabin; L Carreño; E Fernandez-Cruz
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 10.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.